Invasive mold infections in the pediatric setting: current status and new developments. (PubMed, Expert Rev Anti Infect Ther) - May 12, 2026 - "Treatments for IMIs in pediatric patients include mold-active triazoles such as voriconazole and posaconazole, and liposomal amphotericin B. Isavuconazole has recently been approved for clinical use and will be a valuable addition to the antifungal armamentarium. The pharmacology, tolerability, and safety of the newer triazole isavuconazole has been established for the treatment of pediatric patients with IMIs with supportive efficacy data. However, further larger-cohort studies are warranted to define its role relative to the existing mold-active triazoles and liposomal amphotericin B."
Journal • Review • Infectious Disease • Pediatrics • Pulmonary Disease • Respiratory Diseases
|
|
Adilia Warris; Andreas H Groll; Antonio C Arrieta; Pablo Rojo
|